NCT04432233 is a Phase 4 clinical trial of Esomeprazole in Helicobacter Pylori Infection, sponsored by Shanghai Jiao Tong University School of Medicine.

Who is sponsoring NCT04432233?

NCT04432233 is sponsored by Shanghai Jiao Tong University School of Medicine.

What drugs are being tested in NCT04432233?

Interventions in NCT04432233: Esomeprazole, Metronidazole, Levofloxacin.

What condition does NCT04432233 study?

NCT04432233 studies Helicobacter Pylori Infection, Intravenous Drug Usage.

Is NCT04432233 still recruiting?

NCT04432233 is currently status unknown. Last updated 27 August 2020.

Last reviewed 2020-08-27 · How we verify

NCT04432233

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Intravenous Triple Therapy in the Treatment of Helicobacter Pylori Infection and Related Complications Caused by Active Peptic Ulcer Disease

Status unknown Phase 4 Last updated 27 August 2020

What this trial tests

Phase 4 trial testing Esomeprazole in Helicobacter Pylori Infection in 60 participants. Status unknown.

Timeline

15 June 2020

Primary endpoint
15 April 2021

15 June 2021

Quick facts

Lead sponsor	Shanghai Jiao Tong University School of Medicine
Phase	Phase 4
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	60
Start date	15 June 2020
Primary completion	15 April 2021
Estimated completion	15 June 2021
Sites	1 location across China

Drugs / interventions tested

Esomeprazole (esomeprazole) — full drug profile →
Metronidazole (METRONIDAZOLE) — full drug profile →
Levofloxacin (Levofloxacin) — full drug profile →

Conditions studied

Helicobacter Pylori Infection — all drugs for Helicobacter Pylori Infection →
Intravenous Drug Usage — all drugs for Intravenous Drug Usage →

Sponsor

Shanghai Jiao Tong University School of Medicine

Who can join

Adults 18 to 75, any sex, with Helicobacter Pylori Infection or Intravenous Drug Usage. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Helicobacter pylori infection causes active peptic ulcer disease and related complications like bleeding and pyloric obstruction. Usually, clinicians tended to treat Helicobacter pylori infection after active peptic ulcer disease and related complicaitons getting healed, which spent time and money. This study is designed to evaluate the efficacy and safety of intravenous administration of metronidazole, levofloxacin and esomeprazole triple therapy in the treatment of Helicobacter pylori infection combined with peptic ulcer disease related complications.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Esomeprazole

Trials testing the same drug.

NCT07399054 — Efficacy and Safety of Esomeprazole 40 mg IV in Post-Surgical Patients Admitted to the ICU · not yet recruiting
NCT07018635 — A Study to Assess the Effect of Itraconazole, Rifampin, and Acid-Reducing Agents on INCB161734 Pharmacokinetics When Adm · Phase 1 · completed
NCT07268820 — Heartburn, Gastroesophageal Reflux Disease · Phase 4 · recruiting
NCT06851468 — Keverprazan Combined with Amoxicillin for the Treatment of Helicobacter Pylori · NA · not yet recruiting
NCT06793943 — A Study of Interaction of Zasocitinib (TAK-279) With Other Medicines in Healthy Adults · Phase 1 · completed

Other recruiting trials for Helicobacter Pylori Infection

Currently open trials in the same condition.

NCT07285096 — P-CABs-based Bismuth Quadruple Therapy for Helicobacter Pylori Eradication · recruiting
NCT07358130 — Efficacies of Bismuth-amoxicillin-vonoprazan Triple Therapy and Bismuth Quadruple Therapy · NA · recruiting
NCT07165444 — Potassium-Competitive Acid Blocker Versus Proton Pump Inhibitor as A Part of Bismuth Based Quadruple Therapy for Treatme · NA · recruiting
NCT06929962 — VA Dual Sequential Therapy · Phase 4 · recruiting
NCT06959368 — Vonoprazan Evaluation Compared to Standard Triple Therapy in Helicobacter Pylori eRadication · Phase 4 · recruiting

Other Shanghai Jiao Tong University School of Medicine trials

Trials by the same sponsor.

NCT07570810 — Efficacy, Safety, and Tolerability of CS0159 Combined With Semaglutide in MAFLD Patients With Obesity and T2DM · NA · not yet recruiting
NCT07528079 — Organoid-based Sensitivity-guided Chemotherapy for Advanced / Refractory Pediatric Tumors · NA · enrolling by invitation
NCT07535710 — Aclarubicin Plus Cyclophosphamide, Vincristine, and Prednisone (CAOP) in Patients With Previously Treated Cutaneous T-ce · Phase 1, PHASE2 · not yet recruiting
NCT07535762 — Aclarubicin Plus Cyclophosphamide, Vincristine, and Prednisone (CAOP) in Patients With Previously Untreated Peripheral T · Phase 2 · not yet recruiting
NCT07350057 — A Preliminary Clinical Study on the Efficacy of Cyclophosphamide and Sirolimus Combined With VIC-1911 in Preventing Graf · Phase 1 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04432233 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Shanghai Jiao Tong University School of Medicine
Last refreshed: 27 August 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04432233.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing